查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930079

全球液体活检市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量、未来预测（2026-2034）

Liquid Biopsy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 请询问到货日

价格

液体切片市场成长驱动因素

预计2025年全球液体切片市场规模将达到116.6亿美元，2026年将成长至142.3亿美元，到2034年将达到1064.9亿美元。预计该市场在预测期内将以28.61%的复合年增长率成长。这种快速成长主要受癌症发病率上升、对非侵入性诊断技术的需求增加以及分子​​诊断技术进步的推动。

液体切片是指检测和分析血液、脑脊髓液和羊水等生物体液中的循环肿瘤DNA (ctDNA)、游离DNA (cfDNA)、循环肿瘤细胞和生物标记。这些检测方法为癌症诊断、预后评估和治疗方案选择提供了一种微创替代方案，可取代传统的组织活检。

市场规模（依报告年份划分的价值）

  • 市场规模（2025 年）：116.6 亿美元
  • 市场规模（2026 年）：142.3 亿美元
  • 市场规模（预测，2034 年）：1,064.9 亿美元

主要成长驱动因素

全球癌症负担日益加重是推动市场成长的主要因素。根据印度医学研究理事会 (ICMR) 的数据，预计印度癌症病例数将从 2020 年的 139 万例增加到 2022 年的 146 万例，与全球趋势一致。这一激增推动了对早期筛检、疾病监测和精准肿瘤学解决方案的需求。

此外，由于唐氏症等染色体异常的盛行率不断上升，液体活检在非侵入性产前检测 (NIPT) 中发挥重要作用。政府支持的筛检计画以及人们对早期疾病检测意识的提高，进一步推动了液体活检的普及。

美国食品药物管理局 (FDA) 和其他机构对先进癌症检测技术的监管批准，以及持续的临床研究和技术创新，都极大地促进了市场扩张。

市场限制因子

儘管液体活检具有诸多优势，但其市场仍面临着高昂的检测成本和有限的报销等挑战。在美国，每次液体活检的费用可能超过 2000 美元，使其难以用于常规筛检。此外，报销限制，尤其是在早期癌症筛检方面，阻碍了液体活检的更广泛应用，尤其是在印度和中国等发展中国家。

市场区隔分析

依产品分类：

试剂盒和试剂占市场主导地位，预计到 2026 年将占市场占有率的 80.08%，这主要得益于 ctDNA 和 NIPT 检测产品的频繁上市和批准。仪器预计将以适度的速度成长，这得益于 PCR 和 NGS 平台技术的进步。

依应用分类：

到 2026 年，非侵入性产前检测 (NIPT) 将占最大的市场占有率，达到 68.69%，这主要得益于产前筛检需求的成长。肿瘤学领域预计将以更高的复合年增长率成长，这主要得益于其在癌症诊断、治疗监测和復发检测等领域的应用不断扩展。

依最终使用者划分：

到 2026 年，医院将占市场主导地位，市占率高达 75.01%。这主要得益于医院庞大的患者群体以及癌症检测和产前检测的日益普及。临床实验室预计将因诊断基础设施的扩展而实现显着成长。

区域因素

预计到 2025 年，北美将引领全球液体活检市场，市场占有率达到 54.57%，这得益于强劲的研发投入、精准肿瘤学的早期应用以及有利的报销机制。

欧洲紧随其后，这主要得益于政府主导的癌症筛检计画以及对诊断技术创新投入的增加。

预计亚太地区将实现最快增长，这主要得益于癌症发病率的上升、医疗保健覆盖范围的扩大以及中国、日本和印度等国家无创胎儿染色体检测 (NIPT) 的日益普及。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家癌症发生率（2025 年）
  • 主要产业趋势：併购、业务合作
  • 主要公司新产品发布
  • 新冠疫情对市场的影响

第五章 全球液体切片市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 试剂盒及试剂
    • 设备
  • 市场分析、洞察与预测：依应用分类
    • 非侵入性产前检测 (NIPT)
    • 肿瘤学
    • 其他
  • 市场分析、洞察与预测：依最终用户分类
    • 医院
    • 临床实验室
    • 其他
  • 市场分析、洞察与预测：依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美液体切片市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲液体切片市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章 亚太地区液体切片市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他地区亚太地区

第九章：拉丁美洲液体切片市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲液体切片市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）成员国
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • Guardant Health
    • PERSONALIS, INC.
    • FOUNDATION MEDICINE, INC.
    • Natera, Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Menarini Silicon Biosystems, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Bio-Rad Laboratories, Inc.
Product Code: FBI102506

Growth Factors of liquid biopsy Market

The global liquid biopsy market was valued at USD 11.66 billion in 2025 and is projected to grow to USD 14.23 billion in 2026, reaching a substantial USD 106.49 billion by 2034. The market is expected to expand at a compound annual growth rate (CAGR) of 28.61% during the forecast period. This rapid growth is primarily driven by the rising prevalence of cancer, increasing demand for non-invasive diagnostic techniques, and advancements in molecular diagnostics.

Liquid biopsy refers to the detection and analysis of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and biomarkers from biological fluids such as blood, cerebrospinal fluid, and amniotic fluid. These tests provide a minimally invasive alternative to traditional tissue biopsies for cancer diagnosis, prognosis, and therapy selection.

Market Size & Value (As per Report Year)

  • 2025 Market Size: USD 11.66 billion
  • 2026 Market Size: USD 14.23 billion
  • 2034 Forecast Market Size: USD 106.49 billion

Key Growth Drivers

The rising global burden of cancer is a major factor fueling market growth. According to ICMR data, cancer incidence in India increased from 1.39 million in 2020 to 1.46 million in 2022, reflecting a broader global trend. This surge has increased the demand for early screening, disease monitoring, and precision oncology solutions.

In addition, liquid biopsy plays a critical role in non-invasive prenatal testing (NIPT), driven by the increasing prevalence of chromosomal abnormalities such as Down syndrome. Government-supported screening initiatives and growing awareness of early disease detection have further boosted adoption.

Regulatory approvals from agencies such as the U.S. FDA for advanced cancer detection assays, along with continuous clinical research and innovation, are significantly supporting market expansion.

Market Restraints

Despite its advantages, the market faces challenges related to high test costs and reimbursement limitations. In the U.S., liquid biopsy tests can cost over USD 2,000 per test, making them less accessible for routine screening. Additionally, reimbursement restrictions-especially for early-stage cancer screening-limit broader adoption, particularly in developing economies such as India and China.

Segmentation Analysis

By Product:

Kits & reagents dominate the market, accounting for 80.08% share in 2026, due to frequent product launches and approvals for ctDNA and NIPT assays. Instruments are expected to grow at a moderate pace, supported by technological advancements in PCR and NGS platforms.

By Application:

Non-invasive prenatal testing (NIPT) held the largest share at 68.69% in 2026, driven by rising prenatal screening demand. The oncology segment is expected to grow at a higher CAGR, supported by increasing use in cancer diagnosis, therapy monitoring, and recurrence detection.

By End User:

Hospitals dominated the market with a 75.01% share in 2026, owing to high patient footfall and increasing adoption of cancer and prenatal tests. Clinical laboratories are expected to register notable growth due to expanding diagnostic infrastructure.

Regional Insights

North America dominated the global liquid biopsy market with a 54.57% share in 2025, driven by strong R&D investment, early adoption of precision oncology, and favorable reimbursement frameworks.

Europe follows due to government-led cancer screening programs and rising funding for diagnostic innovation.

Asia Pacific is expected to witness the fastest growth, supported by rising cancer prevalence, expanding healthcare access, and growing adoption of NIPT in countries such as China, Japan, and India.

Competitive Landscape

Key players include Guardant Health, Foundation Medicine, Natera, Illumina, Roche, Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories. Companies are focusing on strategic collaborations, clinical trials, and product innovations to strengthen their market presence.

Conclusion

The global liquid biopsy market is poised for strong long-term growth, expanding from USD 11.66 billion in 2025 to USD 106.49 billion by 2034. Rising cancer incidence, increasing preference for non-invasive diagnostics, and advancements in molecular testing technologies are the key growth catalysts. Although high costs and reimbursement challenges remain, continuous innovation, regulatory approvals, and expanding clinical applications are expected to drive widespread adoption, positioning liquid biopsy as a cornerstone of future precision medicine.

Growth Rate CAGR of 28.61% from 2026-2034

Segmentation By Product

  • Kits & Reagents
  • Instruments

By Application

  • Non-invasive Prenatal Testing (NIPT)
  • Oncology
  • Others

By End User

  • Hospitals
  • Clinical Laboratories
  • Others

By Region

  • North America (By Product, By Application, By End User, and By Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Product, By Application, By End User, and By Country/ Sub-region)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Product, By Application, By End User, and By Country/ Sub-region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Product, By Application, By End User, and By Country/ Sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Product, By Application, By End User, and By Country/ Sub-region)
    • GCC (By Application)
    • South Africa (By Application)
    • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, By Key Countries, 2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, & Acquisitions
  • 4.3. New Product Launches, By Key Players
  • 4.4. Impact of COVID-19 on the Market

5. Global Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Kits & Reagents
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Non-invasive Prenatal Testing (NIPT)
    • 5.2.2. Oncology
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinical Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Kits & Reagents
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Non-invasive Prenatal Testing (NIPT)
    • 6.2.2. Oncology
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinical Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Kits & Reagents
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Non-invasive Prenatal Testing (NIPT)
    • 7.2.2. Oncology
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinical Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Spain
      • 7.4.4.1. By Application
    • 7.4.5. Italy
      • 7.4.5.1. By Application
    • 7.4.6. Rest of Europe
      • 7.4.6.1. By Application

8. Asia Pacific Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Kits & Reagents
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Non-invasive Prenatal Testing (NIPT)
    • 8.2.2. Oncology
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinical Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Application
    • 8.4.2. China
      • 8.4.2.1. By Application
    • 8.4.3. India
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Kits & Reagents
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Non-invasive Prenatal Testing (NIPT)
    • 9.2.2. Oncology
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinical Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Kits & Reagents
    • 10.1.2. Instruments
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Non-invasive Prenatal Testing (NIPT)
    • 10.2.2. Oncology
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinical Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Guardant Health
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. PERSONALIS, INC.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. FOUNDATION MEDICINE, INC.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Natera, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Illumina, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. F. Hoffmann-La Roche Ltd
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Menarini Silicon Biosystems, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Thermo Fisher Scientific Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. QIAGEN
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Bio-Rad Laboratories, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 02: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 04: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 05: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 06: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 07: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 08: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 12: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 14: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 16: Spain Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 17: France Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Italy Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: U.K. Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 20: Rest of Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 21: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 24: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: China Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 26: India Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 27: Japan Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Australia Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 29: Southeast Asia Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 30: Rest of Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 31: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 33: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 34: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 35: Brazil Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 36: Mexico Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 37: Rest of Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 38: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 39: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 40: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 41: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 42: GCC Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 43: South Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 44: Rest of Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034

List of Figures

  • Figure 01: Global Liquid Biopsy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Liquid Biopsy Market Value Share (%), By Product, 2025 & 2034
  • Figure 03: Global Liquid Biopsy Market Value Share (%), By Application, 2025 & 2034
  • Figure 04: Global Liquid Biopsy Market Value Share (%), By End User, 2025 & 2034
  • Figure 05: Global Liquid Biopsy Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 07: North America Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 08: North America Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 09: North America Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 10: North America Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 12: North America Liquid Biopsy Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Liquid Biopsy Market Value Share (%), by Country, 2025
  • Figure 14: Europe Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: Europe Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 16: Europe Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 17: Europe Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 18: Europe Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 20: Europe Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 23: Asia Pacific Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 24: Asia Pacific Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 25: Asia Pacific Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 26: Asia Pacific Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 31: Latin America Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 32: Latin America Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 33: Latin America Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 34: Latin America Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Middle East & Africa Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 40: Middle East & Africa Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 41: Middle East & Africa Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 42: Middle East & Africa Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Liquid Biopsy Market Share (%), 2025